PREDILIFE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.05 EUR | +4.44% |
|
-8.44% | +23.68% |
| 2023 | Predilife: a project accredited by Finance Innovation | CF |
| 2023 | Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 289K 311K | Sales 2023 * | - | Capitalization | 26.09M 28.1M |
|---|---|---|---|---|---|
| Net income 2022 * | - | Net income 2023 * | - | EV / Sales 2022 | 79.4 x |
| Net cash position 2022 | 3.52M 3.79M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 92.59% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +4.44% | ||
| 1 week | -8.44% | ||
| Current month | +36.89% | ||
| 1 month | +53.26% | ||
| 3 months | +46.88% | ||
| 6 months | +13.71% | ||
| Current year | +23.68% |
1 week
6.05
8.50
1 month
4.0824.00
Current year
3.6024.00
1 year
3.6024.00
3 years
3.6024.00
5 years
3.6024.00
10 years
3.6024.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Émilien Gauthier
CTO | Chief Tech/Sci/R&D Officer | - | 06-12-31 |
Marion Renelier
LAW | General Counsel | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Vilgrain
BRD | Director/Board Member | 44 | 17-12-31 |
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Antoine Bricard
BRD | Director/Board Member | 56 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 7.05 | +4.44% | 5,105 |
| 24-05-09 | 6.75 | -1.46% | 2,034 |
| 24-05-08 | 6.85 | -8.67% | 9,603 |
| 24-05-07 | 7.5 | +19.05% | 34,903 |
| 24-05-06 | 6.3 | -18.18% | 21,183 |
Real-time Euronext Paris, May 10, 2024 at 11:26 am EDT
More quotes
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.68% | 28.1M | |
| -27.67% | 9.87B | |
| +34.87% | 3.07B | |
| -17.30% | 2.74B | |
| -11.15% | 2.24B | |
| -22.32% | 1.63B | |
| +23.58% | 771M | |
| -1.31% | 760M | |
| -28.57% | 516M | |
| +5.37% | 310M |
- Stock Market
- Equities
- ALPRE Stock
